Duchesnay invests $3 million at its Blainville plant and increases its export capacity
BDC funds Duchesnay manufacturing expansion for domestic pharmaceutical products to go global.
Exporting & Importing
BLAINVILLE — Duchesnay, a specialty pharmaceutical company, announces an investment at its Blainville, Quebec plant. The addition of a blister packaging line to the production chain for its flagship products Diclectin®, Bonjesta®, Pregvit®, Pregvit® folic 5 and Osphena® will allow the company to increase its export capacity, in addition to optimizing its manufacturing site. This $3 million investment will also help provide and maintain quality specialized jobs in Quebec.
Blister packaging of pharmaceutical products being a requirement of authorities in many countries, the addition of this new equipment will serve Duchesnay in pursuit of its international export objectives for its flagship products. As Éric Gervais, Executive Vice President for Duchesnay, mentioned: “This investment is directly in line with Duchesnay’s key strategic axes. As we aim to export to more than 50 additional countries, we must give ourselves the means to achieve our ambitions while keeping all the stages of production here. In addition, in this time of a global pandemic where shortages of essential drugs are frequent, this investment contributes to increase our independence in pharmaceutical production.”
This project was carried out with the participation of the Business Development Bank of Canada (BDC) by providing full financing for this investment.
“BDC is delighted to support the Duchesnay team in its growth,” adds Chantal Rémy, Senior Vice President, Quebec and Atlantic at BDC. “It is a company with high potential, well positioned to meet the challenges related to pharmaceutical production. Its future in international markets is promising and above all, Duchesnay contributes to the economic vitality of Quebec! As the bank for entrepreneurs, we are proud to include them in the BDC family.”